Categories: News

neuro42 Licenses Robot from Johns Hopkins University

SAN FRANCISCO–(BUSINESS WIRE)–neuro42, Inc. (“neuro42” or the “Company”), a medical imaging, robotics, and AI technology company, today announced an exclusive licensing agreement with Johns Hopkins University (“Johns Hopkins”) for their MR compatible robot for head, neck and spine applications, with additional non-exclusive licenses for related technologies and patents. Developed by Dr. Dan Stoianovici, director of the Urology Robotics Program at the Brady Urological Institute and a professor of neurosurgery at the Johns Hopkins University School of Medicine, the robot provides targeted needle insertion with precision depth control. It is designed with nonmagnetic and nonconductive materials to be compatible with magnetic resonance imagers.

“The novel architecture of our imaging system will incorporate the robot to facilitate image-guided interventions during brain biopsies, shunt placements and laser ablations, giving neurosurgeons a more practical intraoperative solution for such procedures than a traditional MRI. We look forward to collaborating with the team at Johns Hopkins to enable safe and effective intraoperative MR treatments using the neuro42 scanner and the robot,” said Abhita Batra, Co-founder and Chief Strategy Officer of neuro42.

About neuro42, Inc.

neuro42, Inc. is a San Francisco, CA based medical technology company focused on diagnostic imaging and image guided surgical interventions of the brain. Founded by a team of successful entrepreneurs and healthcare innovators, the Company is developing and commercializing an intraoperative MR, AI and robotic system that allows easy access to MR imaging for screening, diagnosis and interventions of neurological diseases. Backed by over 30 patents, neuro42’s platform is poised to enhance patient and physician experience with its novel, easy-to-use and portable configuration.

To learn more about the company and its technology, visit neuro42.ai.

LinkedIn: neuro42

Twitter: neuro42

Facebook: neuro42

Contacts

Ashley Areeda

Jive PR + Digital

aareeda@jiveprdigital.com
m: 734.891.4013

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

5 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

6 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

6 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

7 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

9 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

9 hours ago